OncoMatch/Clinical Trials/NCT06222593

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC

Is NCT06222593 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Bicalutamide in combination with Sunitinib for carcinoma, renal cell.

Phase 1/2RecruitingState University of New York at BuffaloNCT06222593Data as of May 2026

Treatment: Bicalutamide in combination with Sunitinib — This is a Phase I/II open-label, efficacy and safety study of bicalutamide in combination with sunitinib in patients with advanced renal cell carcinoma (RCC) who have been treated with a receptor tyrosine kinase inhibitor (RTKI) and experienced disease progression.

Check if I qualify

Extracted eligibility criteria

Cancer type

Renal Cell Carcinoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Must have received: tyrosine kinase inhibitor

TKIs-resistant RCC

Cannot have received: investigational agent or device

Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.

Lab requirements

Blood counts

adequate organ function

Kidney function

adequate organ function

Liver function

adequate organ function

Demonstrate adequate organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

UB/ Great Lakes Cancer Care · Buffalo, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify